INSULET CORP (PODD) Stock
PODD has an Alpha Score of 44 out of 100 (weak), computed on Oct 31, 2026 from 3 of 4 sub-scores. 6 members of Congress disclosed 19 trades in PODD since 2018: 5 purchases and 14 sales, most recently Gilbert Cisneros (partial sale, Sep 18, 2026). 5 of the hedge funds AlphaScala tracks reported PODD in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $131.76M. Company insiders reported 1 open-market buy and 0 sales on SEC Form 4 in the 90 days to Oct 30, 2026. Its trailing P/E ratio is 27.0 and its net margin 12.3% (key statistics as of Oct 22, 2026).
What is PODD's Alpha Score?
How it works →Alpha Score of 44 reflects weak overall profile with weak momentum, weak value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 31, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded INSULET CORP (PODD)?
Most recent: Gilbert Cisneros (partial sale, Sep 18, 2026); records start Mar 2, 2018.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Gil Cisneros D-CA · House | 2026-09-18 | partial sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-08-18 | purchase | $1k – $15k |
| Tina Smith D-MN · Senate | 2026-05-07 | sale | $100k – $250k |
| Tina Smith D-MN · Senate | 2026-04-29 | partial sale | $100k – $250k |
| Markwayne Mullin R-OK · Senate | 2024-01-04 | sale | $1k – $15k |
| Markwayne Mullin R-OK · Senate | 2023-12-22 | partial sale | $1k – $15k |
| Dan Goldman D-NY · House | 2023-07-12 | sale | $1k – $15k |
| Dan Goldman D-NY · House | 2023-04-10 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 29, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
See all PODD political trades →Which hedge funds own PODD?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 865K | $131.76M | +190% |
| Citadel Ken Griffin | 797K | $121.30M | +419% |
| D.E. Shaw David Shaw | 427K | $64.94M | +219% |
| Renaissance Technologies Jim Simons (founder) | 202K | $30.77M | -53% |
| Bridgewater Associates Ray Dalio | 156K | $23.81M | +343% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are INSULET CORP insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 21, 26 | Mcevoy Ashley | President and CEO | BUY | 1.1K | $162K |
SEC Form 4 filings as of Oct 30, 2026
See cluster-buy signals across all tickers →What are PODD's key statistics?
Key statistics as of Oct 22, 2026
How does PODD's valuation compare with the Healthcare sector?
| Metric | PODD | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 27.0 | 27.0 | 96 |
| Net margin | 12.29% | 5.92% | 136 |
| Return on equity | 17.37% | 7.18% | 155 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 1, 2026). P/E excludes loss-making companies.
PODD price chart
Powered by TradingViewWhat does INSULET CORP do?
Insulet Corporation is a medical device company that develops, manufactures, and sells innovative insulin delivery systems, primarily through its Omnipod product platform, for people with insulin-dependent diabetes worldwide. The Omnipod offers a tubeless, wearable Pod that provides up to three days of continuous insulin delivery without needles or tubing, simplifying diabetes management and eliminating multiple daily injections. Key products include the Omnipod 5 Automated Insulin Delivery system, which integrates with third-party continuous glucose monitors via Bluetooth for automated insulin adjustments, and the Omnipod DASH insulin management system controlled by a smartphone-like device. Insulet Corporation also adapts its Pod technology for the subcutaneous delivery of non-insulin drugs in other therapeutic areas through partnerships. Available in over 25 countries across North America, Europe, the Middle East, and Asia Pacific, the company focuses on enhancing patient freedom and reducing the daily burden of diabetes care. Founded in 2000 and headquartered in Acton, Massachusetts, Insulet Corporation leads in tubeless automated insulin delivery solutions.